FDA Sets a July 30 Panel on Replimune’s Melanoma Drug

FDA will convene its Cellular, Tissue, and Gene Therapies Advisory Committee on 30 July 2026 to consider Replimune’s vusolimogene oderparepvec, a biologic proposed for advanced melanoma. The meeting notice, published 8 July, is a procedural document — a date, a docket, a set of deadlines — but for anyone tracking the application it is the most consequential kind: it is when an outside panel of experts reviews the evidence in public, and it front-loads a string of cut-off dates that have already begun to pass.

What is on the table

The application is BLA 125827, a Biologics License Application — the pathway for biological products, reviewed by FDA’s Center for Biologics Evaluation and Research. The product, vusolimogene oderparepvec, is an oncolytic immunotherapy; the proposed indication set out in the notice is narrow and specific: use in combination with the checkpoint inhibitor nivolumab, in adult patients with advanced melanoma who have already been treated with an anti-PD-1 containing regimen. That last clause defines the population — patients whose disease has progressed after the current front-line class of immunotherapy, a setting where the options thin out.

The Cellular, Tissue, and Gene Therapies Advisory Committee is the panel FDA turns to for exactly this kind of product. Its general function, in the notice’s words, is to provide advice and recommendations to the agency on regulatory issues; on 30 July it will meet in open session to discuss and make recommendations on the Replimune application. FDA intends to post its background materials no later than two business days before the meeting.

The deadlines already running

Meeting notices are really deadline notices, and this one stacks several close together — most of them before the meeting itself.

• 20 July 2026 — the date by which electronic and written comments had to reach the docket to be provided to the committee. Comments after this are still taken into consideration by FDA, but they do not go in front of the panel.
• 29 July 2026 — the docket, FDA-2026-N-7231, closes. The electronic filing system accepts comments until 11:59 p.m. ET that day; late filings will not be considered.
• 15 July 2026 — the deadline, already passed, for notifying FDA of a request to make a formal oral presentation during the open public hearing, with a brief statement of the evidence or argument to be presented.
• 30 July 2026 — the meeting. Oral presentations from the public are scheduled for roughly 1:05 to 2:05 p.m. ET; if more people ask to speak than can be accommodated, FDA may run a lottery.

What the meeting decides, and what it doesn't

An advisory committee does not approve anything. It advises: it hears FDA’s review and the sponsor’s presentation, takes public comment, discusses, and often votes on questions the agency puts to it. FDA then makes the licensing decision itself and is not bound by the committee’s recommendation — though it rarely departs from a clear one without explaining why, and the discussion becomes part of the public record on the application. The meeting is where the evidence on a product like this is argued in the open rather than inside a review division.

For a therapy aimed at melanoma that has progressed after anti-PD-1 treatment, that public airing carries weight beyond the single application: the committee’s questions map the evidentiary bar for a class of products. It is the same open-session mechanism FDA is using elsewhere to take public input on emerging therapies — the venue changes, the principle does not. The notice was given under the Federal Advisory Committee Act, and FDA waived the usual in-person location requirement to hold the meeting online.